CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. In this touchENDOCRINOLOGY interview, we caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the mechanism of action of CM-101, and the aims, design and eligibility criteria of the proof-of-concept study.
The abstract entitled ‘Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: a proof-of-concept study‘ was presented at EASL 2023, 21–24 June 2023, Vienna, Austria.
Questions:
- What is the mechanism of action of CM-101? (0:14)
- What were the aims, design, and eligibility criteria of the study? (2:03)
Disclosures: Rifaat Safadi is a consultant for Chemomab.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.
Filmed in coverage of EASL 2023
Access further content on liver disorders
